New combo attack on hard-to-treat lung cancer shows early promise
NCT ID NCT03707938
First seen Nov 03, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This early trial tested a two-pronged approach for people with advanced ALK-positive non-small cell lung cancer. Participants first received a targeted drug (brigatinib), then local treatments like surgery or radiation to any remaining tumors. The goal was to see if this combination is safe and could help control the cancer longer. The study involved 35 adults whose cancer had spread or returned.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.